el-Far M, Fouda M, Yahya R, el-Baz H
Biochemistry Div., Faculty of Science, Mansoura University, Egypt.
J Physiol Biochem. 2004 Dec;60(4):253-8. doi: 10.1007/BF03167070.
Interleukin 10 (IL-10) and interleukin 6 (IL-6) are widely investigated in solid tumors as being important prognostic factors. IL-10 and IL-6 serum levels were measured by enzyme-linked immunosorbent assay from sera taken from 40 non-Hodgkin's lymphoma (NHL) patients before and after treatment and from 20 healthy controls. The patients had been observed for at least 18 months or until death. IL-10 and IL-6 were significantly higher in NHL patients compared to controls. IL-6 was correlated with IL-10 (r = 0.451) and with B symptoms (weight loss > 10% during the last 6 months, unexplained fever and night sweats) (r = 0.447). IL-10 and IL-6 were significantly higher in non survival compared to survival group. High pretreatment IL-10 and IL-6 was associated with poor overall survival. These results show that IL-10 and IL-6 levels are elevated in NHL patients and seem to suggest that simultaneous elevation of IL-10 and IL-6 is a powerful negative prognostic parameter in NHL.
白细胞介素10（IL-10）和白细胞介素6（IL-6）作为重要的预后因素，在实体瘤中得到了广泛研究。采用酶联免疫吸附测定法，对40例非霍奇金淋巴瘤（NHL）患者治疗前后及20例健康对照者血清中的IL-10和IL-6水平进行了检测。对患者进行了至少18个月的观察或直至死亡。与对照组相比，NHL患者的IL-10和IL-6水平显著更高。IL-6与IL-10相关（r = 0.451），与B症状（过去6个月体重减轻> 10%、不明原因发热和盗汗）相关（r = 0.447）。与存活组相比，非存活组的IL-10和IL-6显著更高。治疗前IL-10和IL-6水平高与总体生存率低相关。这些结果表明，NHL患者的IL-10和IL-6水平升高，似乎提示IL-10和IL-6同时升高是NHL中一个有力的不良预后参数。
